Navigation Links
Oral contraceptives safe for women with Lupus erythematosus

Lupus erythematosus (lupus) is a disease in which the body's immune system mistakenly attacks and damages healthy tissues of the skin, joints and internal organs.// A study has found that women who suffer from this disease can take oral contraceptives safely without any complications like increased risk of flares, or periods of increased disease activity, that characterize the disease.

The study was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH).

The entire study can be described as stated by the researchers as a 15-center study of 183 women with inactive or stable lupus. The women who were taking oral contraceptives (triphasic 35 μg.ethinylestradiol/0.5-1 mg norethindrone for twelve 28-day cycles) had no statistically significant difference in the occurrence of flares than those taking a placebo. Severe flares occurred in about 7 percent of the women, regardless of whether they received oral contraceptives or placebo. A severe flare was defined by several criteria, including the presence of new or worsening central nervous system involvement; inflammation of the blood vessels, kidneys and/or muscles; and/or blood problems, including low platelet count and destruction of the red blood cells.

As put by the authors of the study, "There are settings in which estrogens might provide benefit. Among women with lupus there is a high elective abortion rate – approaching 23 percent of pregnancies – which may reflect a failure of the birth control method used or the absence of an adequate birth control program."

In the words of NIAMS Director Stephen I. Katz, M.D., Ph.D, "Estrogen, as used in this study, appears to be safe in the majority of women with stable disease.This research brings us another step forward in improving quality of life for people with rheumatic disease."

'"/>




Page: 1

Related medicine news :

1. Hormone contraceptives lead to bone problems
2. Indian Health Ministry approves sale of Emergency contraceptives as over the counter drug
3. Lower doses of oral contraceptives helpful in treating acne
4. Dermaseptins: Potent vaginal contraceptives
5. Do oral contraceptives offer protective cover against endometrial cancer?
6. Transdermal HRT not cardioprotective in postmenopausal women with CAD
7. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
8. Starvation in pregnant women can cause heart disease to their children
9. Brisk Walking lowers memory loss in women
10. Young womens woes
11. Young womens woes
Post Your Comments:
(Date:7/8/2008)... SKINTASTIC™ is p...ed Evolence®--the latest injectable collagen f...owntime beauty treatments. EVOLENCE® utilizes ...as a preferred medical grafting substance due to i... , N. Dallas/Plano, TX (PR...
(Date:7/8/2008)... HARRISBURG, Pa., July 8 /PRNewswire-USNewswire...ecutive order regarding the Pennsylvania Health,Ca...fter the law,authorizing its operation expired on ...hen PHC4 was allowed to "sunset",by the General As...ction., The Rendell administration is committed t...
(Date:7/8/2008)...,This new executive team will give the men we serv..., said Carl J. Bentley, President, M.I. Board of ...July 8 /PRNewswire/ -- The Mariners Inn shelter an...ng the appointment of Jim Hartz as,chief executive...cer., "Both Jim and David are outstanding leaders...
(Date:7/8/2008)... Reductions in Iron Blood Levels Associated with...rial Disease , Men with peripheral arterial dis...rial in which their iron stores were reduced by bl...tive to men in the trial who did not undergo blood... that lower levels of iron in the blood may be ass...
Breaking Medicine News(10 mins):Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 2Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 3Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:Mariners Inn Announces New Executive Leadership 2Health News:Also in the July 8 JNCI 2Health News:Also in the July 8 JNCI 3Health News:Also in the July 8 JNCI 4
...enue, Newcastle-under-Lyme, Staffordshire, was cha...gs died shortly after birth at a Shropshire hospit...essive force. The doctor said that he used a sucti...as not in the right position. A Birmingham Crown ...
...formed testicular cells obtained from male mice in...cks that have the remarkable ability to transform ...elief the same could be achieved in humans, helpin...ated with the derivation of embryonic stem cells f...
...st two times since 1990 in America. Labor, deliver..., are now being increasingly manipulated to suit t... A pregnant Super Bowl fan in Pittsburg told news ...for an early labor induction so that she would not...
...clinical psychologist and author, a lot of woman p...vereater’s who try to mask their depression with f... generally do not seek treatment for their depress...unity and family members don't recognize depressio...
Other Medicine News:Health News:To Wait Or Not 2Health News:African-American Women Need To Seek Advice On depression 2
(Date:7/8/2008)...tudy of Clevudine versus Viread(R) versus Cle...titis B, PRINCETON, N.J., July 8 /PRNewswire-Firs...on AIDS and Viral Hepatitis (ANRS), with the suppo... Sciences, Inc. (Nasdaq: GILD ),has initiated th...(R),(tenofovir disoproxil fumarate) administered s...
(Date:7/7/2008)...resence Includes ANA598 and ANA773 Acting via ...hanisms Conference Call Today at ...all/ -- Anadys Pharmaceuticals,Inc. (Nasdaq: AND...nvestigation of the Toll-Like Receptor-7 (TLR7) me...Based on preclinical pharmacology testing,and the ...
(Date:7/7/2008).../- Light Sciences Oncology, Inc.,(LSO...atients with benign,prostatic hyperplasia (BPH), o...n Therapy(TM) (Litx(TM)), an innovative light-acti...to conduct a 12-patient, Phase I/II,dose-escalatio... as a,40-patient, Phase IIa study in Australia, ex...
(Date:7/7/2008)...ire-FirstCall/ -- GeoVax Labs, Inc. (OTC,Bulletin ...opharmaceutical,company specializing in the preven...rovided an operational update on the company,s pro...clinical trial testing and,plans to proceed into t...e,successful human trials evaluating GeoVax AIDS v...
Breaking Medicine Technology:Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 2Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 3Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 2Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 3GeoVax Reports Progress on Its AIDS Vaccine Technology 2GeoVax Reports Progress on Its AIDS Vaccine Technology 3GeoVax Reports Progress on Its AIDS Vaccine Technology 4GeoVax Reports Progress on Its AIDS Vaccine Technology 5Paradigm shift 3A Switch for programmed cell death promotes spread of glioblastoma 14025 1Paradigm shift 3A Switch for programmed cell death promotes spread of glioblastoma 14025 2Amphibians respond behaviorally to impact of clear cutting 2464 1Amphibians respond behaviorally to impact of clear cutting 2464 2Epigenetic changes discovered in major psychosis 2461 1Epigenetic changes discovered in major psychosis 2461 2Genesis Pharmaceuticals Changes Auditors 14020 1Genesis Pharmaceuticals Changes Auditors 14020 2
...FIELD, Mass.--(BUSINESS WIRE)--Jul 6, 2007 - Busin...race by pharmaceutical and,biotechnology companies...genesis treatment for cardiovascular disease. Whil...fi-Aventis, Boston,Scientific, Baxter, and Genzyme...ising new biological therapy for advanced,coronary...
...DGEWATER, N.J., July 05, 2007 /PRNewswire/ -- Resu...trolled, open-label, Phase,3 study showed that 77 ...ults taking PREZISTA(TM) (darunavir) 600 mg tablet...plus an optimized,background regimen (OBR) of anti...ad of <400 copies/mL at week 48, compared to 68,pe...
Other Medicine Technology:BusinessWeek Article Highlights Promising Breakthrough Treatment,for Advanced Coronary Artery Disease 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8
Titanium. Curved 18 mm shafts with 1.5 wide grasping tip. Flat, serrated cross action handle with dull finish.
Titanium. Designed to easily fold the hydroview lens. Will also fold many styles of soft intraocular lenses. Unique cross-action design facilitates folding of the lens.
30 degree angled tip with 45 mm tip opening. Stainless.
Insertion forcep used for the Hydroview lens. Manufactured in titanium.
Medicine Products: